Cowen Starts Celldex Therapeutics (CLDX) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CLDX Hot Sheet
Price: $28.69 -0.97%
Rating Summary:
18 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 15
Rating Summary:
18 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 15
Join SI Premium – FREE
Cowen initiated coverage on Celldex Therapeutics (NASDAQ: CLDX) with an Outperform rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.
Shares of Celldex Therapeutics closed at $14.16 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Starts Unusual Machines (UMAC) at Outperform
- Citi Starts Kewpie Corp (2809:JP) at Neutral
- Needham Assumes Benchmark (BHE) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
